Lenacapavir
Coverage of Lenacapavir in the Nexus archive.
- Lenacapavir will slow HIV infections if there's enough of it and it reaches at-risk groups
Lenacapavir is an HIV prevention injection administered twice a year, offering an improvement over daily pills for high-risk groups. Its long-term effectiveness depends on sufficient supply and distribution to those at risk.
- South Africa: Over 1,000 in Western Cape Initiated on Lenacapavir - South African News Briefs - July 9, 2026
Over 1,000 individuals in South Africa's Western Cape have been initiated on Lenacapavir, as reported by allAfrica. The article highlights the implementation of this treatment in the region.
- Malawi: United States Delivers Breakthrough HIV Prevention Medication to Malawi
The United States government delivered lenacapavir, a new HIV prevention medication, to Malawi. The shipment was handed over to Malawi's Minister of Health Madalitso Baloyi by Chargé d'Affaires Jonathan Fischer at Lilongwe's Area 25 Health Center on July 2.
- South Africa: Gauteng Health Exceeds Lenacapavir Rollout Targets
The Gauteng Department of Health (GDoH) has surpassed its targets for the Lenacapavir rollout programme in its first month, marking a significant milestone in the distribution of the HIV prevention drug.
- Africa: 'One Injection Protects Up to Six Months' - What Is New HIV Drug Lenacapavir?
South Africa has become the ninth African country to introduce the long-acting HIV prevention drug lenacapavir, which offers protection for up to six months. Experts are discussing its mechanism, supply-demand concerns, and challenges in developing an HIV vaccine.
- Mass rollout planned across Southern Africa for new HIV drug
The HIV drug Lenacapavir, offering over 99% protection and administered twice yearly, is set for mass rollout in Southern Africa. The treatment has been approved after years of research and will be distributed across South Africa, Zambia, Eswatini, Zimbabwe, Lesotho, and Mozambique.
- South Africa: Did US Aid Cuts Break Precisely the Things We Need Most for the Lenacapavir Rollout?
South Africa launched a new six-monthly HIV prevention injection, but infrastructure for HIV services has been dismantled due to U.S. aid cuts. The article questions whether the new technology can be successfully delivered without the previously established pathways.
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK acquired Nuvalent, a cancer drug developer, in a $10.6 billion deal to expand its oncology portfolio, while Merck and Gilead Sciences reported success in final-stage trials for a once-weekly HIV pill combining their experimental drugs. The GSK acquisition highlights ongoing biopharma industry consolidation as companies bolster pipelines amid generic competition.
- Highly effective prevention drug arrives in South Africa, which has world’s highest HIV burden
South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention. The president describes it as a turning point in a country with the world’s highest HIV burden.
- Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people
Gilead's HIV drug lenacapavir has the potential to transform HIV treatment, but the company is preventing millions of low-income patients from accessing it. The article criticizes the pharmaceutical company for prioritizing profit over equitable distribution.